Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Thrombocythemia, Essential 1Prostatic Neoplasms 1Polycythemia Vera 1Neoplasms, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1

Interventions

Dexamethasone 17Bortezomib 11pomalidomide 10carfilzomib 6Lenalidomide 4imetelstat 3fludarabine 3daratumumab 3Standard of Care 3Panobinostat 3venetoclax 2siltuximab 2elotuzumab 2Cyclophosphamide 2Arsenic Trioxide 2spartalizumab 1shark cartilage extract 1selinexor 1saracatinib 1ricolinostat 1resiquimod 1poly ICLC 1plitidepsin 1pembrolizumab 1pazopanib 1motexafin gadolinium 1marizomib 1liposomal doxorubicin 1lestaurtinib 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Plasma Cell × lestaurtinib × Clear all
NCT00242827 2012-08-23

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Terminated
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡